© 2026 Stocks Telegraph All rights reserved.
Most stock quote data provided by Financial Modeling Prep
Beyond Air, Inc. (XAIR) stock declined over -0.35%, trading at $0.48 on NASDAQ, down from the previous close of $0.48. The stock opened at $0.47, fluctuating between $0.46 and $0.52 in the recent session.
| Filing Date | Accepted Date | |
|---|---|---|
| Filing Date | Accepted Date | |
|---|---|---|
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Jun 25, 2026 | 0.47 | 0.52 | 0.46 | 0.48 | 309.07K |
| Jun 24, 2026 | 0.49 | 0.52 | 0.47 | 0.48 | 566.41K |
| Jun 23, 2026 | 0.39 | 0.47 | 0.39 | 0.47 | 466.11K |
| Jun 22, 2026 | 0.36 | 0.41 | 0.36 | 0.41 | 299.3K |
| Jun 18, 2026 | 0.36 | 0.40 | 0.36 | 0.36 | 239.87K |
| Jun 17, 2026 | 0.38 | 0.39 | 0.34 | 0.37 | 245.52K |
| Jun 16, 2026 | 0.37 | 0.38 | 0.33 | 0.35 | 284.98K |
| Jun 15, 2026 | 0.38 | 0.40 | 0.37 | 0.37 | 143.45K |
| Jun 12, 2026 | 0.39 | 0.40 | 0.36 | 0.37 | 129.01K |
| Jun 11, 2026 | 0.39 | 0.39 | 0.35 | 0.38 | 240.29K |
| Jun 10, 2026 | 0.40 | 0.40 | 0.37 | 0.38 | 284.98K |
| Jun 09, 2026 | 0.41 | 0.44 | 0.39 | 0.39 | 255.73K |
| Jun 08, 2026 | 0.43 | 0.44 | 0.40 | 0.41 | 212.84K |
| Jun 05, 2026 | 0.46 | 0.46 | 0.40 | 0.41 | 149.16K |
| Jun 04, 2026 | 0.44 | 0.47 | 0.43 | 0.45 | 225.93K |
| Jun 03, 2026 | 0.47 | 0.47 | 0.44 | 0.44 | 80.73K |
| Jun 01, 2026 | 0.48 | 0.51 | 0.45 | 0.49 | 232.26K |
| May 29, 2026 | 0.45 | 0.49 | 0.43 | 0.46 | 165.29K |
| May 28, 2026 | 0.44 | 0.49 | 0.42 | 0.45 | 423.37K |
| May 27, 2026 | 0.42 | 0.45 | 0.42 | 0.43 | 158.05K |
Beyond Air, Inc. functions as a specialized entity involved in both the development of medical devices and biopharmaceutical solutions. A central part of its operations is the LungFit platform, an innovative system that generates and delivers nitric oxide. Within this platform, LungFit PH is currently available, used to address persistent pulmonary hypertension in infants. Furthermore, the company is advancing LungFit PRO, a product intended for various viral lung ailments like community-acquired viral pneumonia (including COVID-19) and bronchiolitis in hospital settings. It is also creating LungFit GO, which aims to treat nontuberculous mycobacteria infections. The organization adopted its current name, Beyond Air, Inc., in June 2019, having previously been known as AIT Therapeutics, Inc. Its headquarters are situated in Garden City, New York.
| Employees | 107 |
| Beta | 0.23 |
| Sales or Revenue | $3.71M |
| 5Y Sales Change% | -0.547% |
| Fiscal Year Ends | March |
| Sector | Healthcare |
| Industry | Medical - Devices |